Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 38

Sort by

Sort Order Select

Journal Articles

Rituximab Reduces Immunogenicity and Increases Complete Remissions without Minimal Residual Disease in Relapsed/Refractory Hairy Cell Leukemia Patients Receiving Moxetumomab Pasudotox

Robert J. Kreitman, Constance M. Yuan, Hao-Wei Wang, Hong Zhou, Mark Raffeld, Liqiang Xi, Evgeny Arons, Julie Feurtado, Lacey James, Raul C. Braylan, Katherine R. Calvo, Irina Maric, Ira Pastan

Blood (2024) 144 (Supplement 1): 6791.

https://doi.org/10.1182/blood-2024-199569

Published: 2024

Journal Articles

Moxetumomab Pasudotox-Tdfk in Heavily Pretreated Patients with Relapsed/Refractory Hairy Cell Leukemia (HCL): Long-Term Follow-up from the Pivotal Phase 3 Trial

Robert J. Kreitman, MD, Claire E. Dearden, MD FRCP, FRCPath, Pier Luigi Luigi Zinzani, MD, Julio Delgado, Tadeusz Robak, MD, Philipp D le Coutre, MD, Bjorn T. Gjertsen, MD PhD, Xavier Troussard, MD, Gail J. Roboz, MD, Lionel Karlin, MD, Douglas E Gladstone, MD, Nataliya Kuptsova-Clarkson, MD, Shiyao Liu, Priti Patel, MD, Wyndham Wilson, MD, Ira Pastan, MD, Francis J. Giles, MD FRCPI, FRCPath

Blood (2019) 134 (Supplement_1): 2808.

https://doi.org/10.1182/blood-2019-122307

Published: 2019

Journal Articles

Molecular Remissions with Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox Are Associated with Improved Complete Remission Durations during Phase I and III Testing

Evgeny Arons, PhD, Daniel Gorelik, Maryalice Stetler-Stevenson, MD PhD, Constance M. Yuan, MD PhD, Mark Sokolsky, Hong Zhou, Nai Shun (nancy) Yao, MD, Shannon Marshall, PhD, Katherine Potocka, Erin Fykes, Ira Pastan, MD, Robert J. Kreitman, MD

Blood (2018) 132 (Supplement 1): 1861.

https://doi.org/10.1182/blood-2018-99-113419

Published: 2018

Journal Articles

Minimal residual hairy cell leukemia eradication with moxetumomab pasudotox: phase 1 results and long-term follow-up

Robert J. Kreitman, Martin S. Tallman, Tadeusz Robak, Steven Coutre, Wyndham H. Wilson, Maryalice Stetler-Stevenson, David J. FitzGerald, Linda Santiago, Guozhi Gao, Mark C. Lanasa, Ira Pastan

Blood (2018) 131 (21): 2331–2334.

https://doi.org/10.1182/blood-2017-09-803072

Published: 2018

Includes: Supplemental data

Journal Articles

Negative Minimal Residual Disease Associated with Extended Response to Moxetumomab Pasudotox in Patients with Relapsed/Refractory Hairy Cell Leukemia: Long-Term Follow-up of Bone Marrow Immunohistochemistry Analyses from a Phase 1 Study

Robert Kreitman, MD, Martin S. Tallman, MD, Tadeusz Robak, MD PhD, Steven Coutre, MD, Shannon Marshall, PhD, Jie Yang, PhD, Ira Pastan, MD, Nai Shun (Nancy) Yao, MD

Blood (2017) 130 (Supplement 1): 2765.

https://doi.org/10.1182/blood.V130.Suppl_1.2765.2765

Published: 2017

Journal Articles

Phase 1 study of the anti-CD22 immunotoxin moxetumomab pasudotox for childhood acute lymphoblastic leukemia

Alan S. Wayne, Nirali N. Shah, Deepa Bhojwani, Lewis B. Silverman, James A. Whitlock, Maryalice Stetler-Stevenson, Weili Sun, Meina Liang, Jie Yang, Robert J. Kreitman, Mark C. Lanasa, Ira Pastan

Blood (2017) 130 (14): 1620–1627.

https://doi.org/10.1182/blood-2017-02-749101

Published: 2017

Includes: Supplemental data

Journal Articles

5-Azacytidine Prevents Relapse from Discrete Bone Marrow Sites in Leukemia Xenografts Treated with CD22-Targeting Immunotoxin Moxetumomab Pasudotox

Fabian Mueller, MD, Tyler Cunningham, Stephanie Stookey, Chin-Hsien Tai, Alan S. Wayne, MD, Ira Pastan, MD

Blood (2016) 128 (22): 2810.

https://doi.org/10.1182/blood.V128.22.2810.2810

Published: 2016

Journal Articles

Immunotoxin Activity Against B-Lineage Leukemia and Lymphoma Is Exposure Time Dependent: Implications for Trial Design

Fabian Mueller, MD PhD, Xiu-Fen Liu, PhD, Alan S. Wayne, MD, Ira Pastan, MD

Blood (2015) 126 (23): 1332.

https://doi.org/10.1182/blood.V126.23.1332.1332

Published: 2015

Journal Articles

High Response Rate of Moxetumomab Pasudotox in Relapsed/Refractory Hairy Cell Leukemia Includes Eradication of Minimal Residual Disease: Potential Importance for Outcome

Robert J. Kreitman, MD, Evgeny Arons, PhD, Martin S Tallman, MD, Robak Tadeusz, MD PhD, Steven Coutre, MD, Wyndham H Wilson, MD PhD, Maryalice Stetler-Stevenson, MD PhD, Constance M. Yuan, MD PhD, Mark Lanasa, MD PhD, David JP FitzGerald, PhD, Ira Pastan, MD

Blood (2015) 126 (23): 4161.

https://doi.org/10.1182/blood.V126.23.4161.4161

Published: 2015

Journal Articles

Immunotoxins for leukemia

Alan S. Wayne, David J. FitzGerald, Robert J. Kreitman, Ira Pastan

Blood (2014) 123 (16): 2470–2477.

https://doi.org/10.1182/blood-2014-01-492256

Published: 2014

Journal Articles

Pharmacokinetic Analysis Of Response In Hairy Cell Leukemia Treated By Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox

Robert J. Kreitman, MD, Evgeny Arons, PhD, Maryalice Stetler-Stevenson, MD, PhD, Wyndham H Wilson, MD, PhD, David J. P. FitzGerald, PhD, Ira Pastan, MD

Blood (2013) 122 (21): 2871.

https://doi.org/10.1182/blood.V122.21.2871.2871

Published: 2013

Journal Articles

Resolution of Hairy Cell Leukemia Minimal Residual Disease by Both BRAF and Clone-Specific Real-Time Quantitative PCR (RQ-PCR) After Treatment with Moxetumomab Pasudotox.

Robert J. Kreitman, MD, Evgeny Arons, PhD, Sapolsky Jeffrey, Laura Roth, Hong Zhou, BS, Maryalice Stetler-Stevenson, MD, PhD, Wyndham H. Wilson, MD, PhD, Mark Raffeld, MD, David J. P. FitzGerald, PhD, Ji Fei, PhD, Ramy Ibrahim, MD, Ira Pastan, MD

Blood (2012) 120 (21): 2896.

https://doi.org/10.1182/blood.V120.21.2896.2896

Published: 2012

Journal Articles

Decreased Expression of Diphthamide Genes Is Responsible for the Resistance to the Anti-CD22 Immunotoxin Moxetumomab Pasudotox (m. pasudotox) in Acute Lymphoblastic Leukemia (ALL)/Non-Hodgkin Lymphoma (NHL) Cell Lines.

Hui Wei, Laiman Xiang, Alan S Wayne, MD, Ira Pastan, MD

Blood (2012) 120 (21): 2443.

https://doi.org/10.1182/blood.V120.21.2443.2443

Published: 2012

Journal Articles

The HLA-DRB1*11 Antigen Is Preferentially Expressed in Hairy Cell Leukemia, Particularly in Patients Who Had Hemolytic Uremic Syndrome with Recombinant Immunotoxin BL22.

Evgeny Arons, PhD, Laura Roth, Sharon Adams, CHS, Jeffery Sapolsky, Ira Pastan, MD, Robert J. Kreitman, MD

Blood (2012) 120 (21): 2488.

https://doi.org/10.1182/blood.V120.21.2488.2488

Published: 2012

Journal Articles

A New High Activity Anti-CD22 Chimeric Antigen Receptor (CAR) Targeting B Cell Leukemia.

Waleed Haso, M.S., Daniel W. Lee, III, MD, Ira Pastan, MD, Dimiter S. Dimitrov, Ph.D, Crystal L Mackall, MD, Rimas J Orentas, PhD

Blood (2012) 120 (21): 2611.

https://doi.org/10.1182/blood.V120.21.2611.2611

Published: 2012

Journal Articles

Regression of Adult T-Cell Leukemia with Anti-CD25 Recombinant Immunotoxin LMB-2 Preceded by Chemotherapy

Robert J. Kreitman, MD, Rajat Singh, Maryalice Stetler-Stevenson, MD, PhD, Thomas A. Waldmann, MD, Ira Pastan, MD

Blood (2011) 118 (21): 2575.

https://doi.org/10.1182/blood.V118.21.2575.2575

Published: 2011

Journal Articles

A Novel Anti-CD22 Immunotoxin, Moxetumomab Pasudotox: Phase I Study in Pediatric Acute Lymphoblastic Leukemia (ALL)

Alan S Wayne, MD, Deepa Bhojwani, MD, Lewis B. Silverman, MD, Kelly Richards, RN, Maryalice Stetler-Stevenson, MD, PhD, Nirali N Shah, MD, Sima Jeha, MD, Ching-Hon Pui, MD, Manuela Buzoianu, PhD, David J. FitzGerald, PhD, Robert J. Kreitman, MD, Ramy Ibrahim, MD, Ira Pastan, MD

Blood (2011) 118 (21): 248.

https://doi.org/10.1182/blood.V118.21.248.248

Published: 2011

Journal Articles

Generation and Optimization of a Chimeric Antigen Receptor Against CD22: A New Immunotherapeutic Agent for Treating B Lineage Leukemia and Lymphoma

Rimas J Orentas, PhD, Waleed Haso, B.S., Richard A. Morgan, Ira Pastan, MD, Crystal L Mackall, MD

Blood (2011) 118 (21): 4313.

https://doi.org/10.1182/blood.V118.21.4313.4313

Published: 2011

Journal Articles

A Phase 1 Study of Moxetumomab Pasudotox, An Anti-CD22 Recombinant Immunotoxin, In Relapsed/Refractory Hairy Cell Leukemia (HCL): Updated Results

Robert J. Kreitman, MD, Martin S. Tallman, MD, Steven Coutre, MD, Tadeusz Robak, MD, PhD, Wyndham H. Wilson, MD, PhD, Maryalice Stetler-Stevenson, MD, PhD, Pierre Noel, MD, David J. FitzGerald, PhD, Manuela Buzoianu, PhD, Robert J. Lechleider, MD, Ira Pastan, MD

Blood (2010) 116 (21): 2516.

https://doi.org/10.1182/blood.V116.21.2516.2516

Published: 2010

Journal Articles

Complete Remissions In 3 of 12 Patients with Pediatric Acute Lymphoblastic Leukemia (ALL) During Phase I Testing of the Anti-CD22 Immunotoxin Moxetumomab Pasudotox

Alan Wayne, MD, Deepa Bhojwani, MD, Kelly Richards, RN, Maryalice Stetler-Stevenson, MD, PHD, Lewis B. Silverman, MD, Sima Jeha, MD, Ching-Hon Pui, MD, Jennifer McDevitt, PharmD, PhD, David J. FitzGerald, PhD, Robert J. Kreitman, MD, Robert J. Lechleider, MD, Ira Pastan, MD

Blood (2010) 116 (21): 3246.

https://doi.org/10.1182/blood.V116.21.3246.3246

Published: 2010

NARROW

Rituximab Reduces Immunogenicity and Increases Complete Remissions without Minimal Residual Disease in Relapsed/Refractory Hairy Cell Leukemia Patients Receiving Moxetumomab Pasudotox

Moxetumomab Pasudotox-Tdfk in Heavily Pretreated Patients with Relapsed/Refractory Hairy Cell Leukemia (HCL): Long-Term Follow-up from the Pivotal Phase 3 Trial

Molecular Remissions with Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox Are Associated with Improved Complete Remission Durations during Phase I and III Testing

Minimal residual hairy cell leukemia eradication with moxetumomab pasudotox: phase 1 results and long-term follow-up

Negative Minimal Residual Disease Associated with Extended Response to Moxetumomab Pasudotox in Patients with Relapsed/Refractory Hairy Cell Leukemia: Long-Term Follow-up of Bone Marrow Immunohistochemistry Analyses from a Phase 1 Study

Phase 1 study of the anti-CD22 immunotoxin moxetumomab pasudotox for childhood acute lymphoblastic leukemia

5-Azacytidine Prevents Relapse from Discrete Bone Marrow Sites in Leukemia Xenografts Treated with CD22-Targeting Immunotoxin Moxetumomab Pasudotox

Immunotoxin Activity Against B-Lineage Leukemia and Lymphoma Is Exposure Time Dependent: Implications for Trial Design

High Response Rate of Moxetumomab Pasudotox in Relapsed/Refractory Hairy Cell Leukemia Includes Eradication of Minimal Residual Disease: Potential Importance for Outcome

Immunotoxins for leukemia

Pharmacokinetic Analysis Of Response In Hairy Cell Leukemia Treated By Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox

Resolution of Hairy Cell Leukemia Minimal Residual Disease by Both BRAF and Clone-Specific Real-Time Quantitative PCR (RQ-PCR) After Treatment with Moxetumomab Pasudotox.

Decreased Expression of Diphthamide Genes Is Responsible for the Resistance to the Anti-CD22 Immunotoxin Moxetumomab Pasudotox (m. pasudotox) in Acute Lymphoblastic Leukemia (ALL)/Non-Hodgkin Lymphoma (NHL) Cell Lines.

The HLA-DRB1*11 Antigen Is Preferentially Expressed in Hairy Cell Leukemia, Particularly in Patients Who Had Hemolytic Uremic Syndrome with Recombinant Immunotoxin BL22.

A New High Activity Anti-CD22 Chimeric Antigen Receptor (CAR) Targeting B Cell Leukemia.

Regression of Adult T-Cell Leukemia with Anti-CD25 Recombinant Immunotoxin LMB-2 Preceded by Chemotherapy

A Novel Anti-CD22 Immunotoxin, Moxetumomab Pasudotox: Phase I Study in Pediatric Acute Lymphoblastic Leukemia (ALL)

Generation and Optimization of a Chimeric Antigen Receptor Against CD22: A New Immunotherapeutic Agent for Treating B Lineage Leukemia and Lymphoma

A Phase 1 Study of Moxetumomab Pasudotox, An Anti-CD22 Recombinant Immunotoxin, In Relapsed/Refractory Hairy Cell Leukemia (HCL): Updated Results

Complete Remissions In 3 of 12 Patients with Pediatric Acute Lymphoblastic Leukemia (ALL) During Phase I Testing of the Anti-CD22 Immunotoxin Moxetumomab Pasudotox

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only